Copenhagen, June 19, 2026, 11:04 (CEST)
- Novo Nordisk B shares traded up around 5% at 294.4 Danish crowns. The OMX Copenhagen 25 index gained 1.67%.
- Europe’s STOXX 600 edged higher, with a boost from healthcare stocks like Novo and AstraZeneca as investors favored more defensive names.
- Novo shares climbed even as the company dealt with an IT security event and kept going head-to-head with Eli Lilly in the oral weight-loss drug battle.
Novo Nordisk’s B shares traded in Copenhagen climbed roughly 5% Friday late morning. It was a strong move for Denmark’s top healthcare stock, giving a boost to the local index.
Shares traded at 294.4 Danish crowns, up from Monday’s close of 280.1, after touching 295.1 crowns earlier. The OMX Copenhagen 25 index added 28.86 points, or 1.67%, to 1,773.22.
Novo’s size is still enough to move the market in Copenhagen. The OMXC25, per Nasdaq, tracks the 25 biggest and most-traded stocks by market value on Nasdaq Copenhagen. Novo sat at 12.11% of the index, according to the March 31 fact sheet.
Copenhagen traded on a normal schedule. Nasdaq’s list of Copenhagen stock market holidays for 2026 does not show June 19 as a break. Regular hours are still 0900-1700 CEST. In the U.S., Novo’s American depositary receipt sat out because U.S. stock markets paused for Juneteenth. The ADR last changed hands at $43.19 on Thursday.
The wider European market was firmer. According to Reuters, the STOXX 600 added 0.2% by 0841 GMT. Healthcare stocks like Novo and AstraZeneca led gains as traders moved toward sectors considered safer in choppy markets. Defensive stocks are seen as having sales that don’t swing as much with the economy.
Novo shares rose even after the company reported a cyber incident. Novo said it found unauthorised access in some internal IT systems, took parts of its systems offline, and discovered that some non-public data, including personal information, was copied without approval. Core business was not affected, Novo said.
Cyber gang FulcrumSec says it took over a terabyte of Novo data and demanded $25 million, Reuters reported this week. The report said Reuters could not verify the authenticity of the leaked data. Thomas Willkan at cybersecurity firm Lab-1 told Reuters the group is “usually quite legit” about its hacks and claims. Reuters
Obesity drugs remain the main equity narrative. Novo Nordisk and Eli Lilly are both pushing ahead in the GLP-1 drug market, where the medicines act like a gut hormone to curb appetite and manage blood sugar. Novo CEO Mike Doustdar said this week the firm will file for Chinese approval of oral Wegovy “very soon,” adding that means “a few months.” Reuters
Investors are expected to watch that closely. Doustdar said scaling up production of the weight-loss pill would be tough for competitors, saying few have “that level” of capacity. But Lilly is already ahead in China, having filed for marketing approval for its once-daily oral drug orforglipron, according to Reuters. Reuters
Novo’s problems aren’t solved by one morning’s bounce. The move shows there’s still demand for the shares when healthcare is strong and investors believe in the oral Wegovy angle. But expectations aren’t what they were during the boom.
Risks pull in the other direction. A bigger data breach, Lilly moving quicker in China, cheaper generics after semaglutide loses patent protection, or new price cuts in obesity meds could hit the recovery instead of pushing it further. Friday’s market move signals a break for now; the question is if it holds.
